<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02431260</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 54329-101</org_study_id>
    <nct_id>NCT02431260</nct_id>
  </id_info>
  <brief_title>An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies</brief_title>
  <official_title>A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of INCB054329 given to patients with advanced malignancies that will be
      conducted in three treatment groups. Each treatment group will have three parts; a dose
      escalation (Part 1), an intra-patient dose titration (Part 2), and an expansion (Part 3).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">January 31, 2018</completion_date>
  <primary_completion_date type="Actual">January 31, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AE)</measure>
    <time_frame>up to 30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of INCB054329 will be determined by the use of validated assays</measure>
    <time_frame>Day 1, 2, 8, 15 and 16 of Cycle 1, up to 24 months (end of treatment )</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Baseline through end of study, up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Baseline through end of study, up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Baseline through end of study, up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Baseline through end of study, up to 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Solid Tumors and Hematologic Malignancy</condition>
  <arm_group>
    <arm_group_label>INCB054329 Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB054329 Monotherapy</intervention_name>
    <description>Initial cohort dose of INCB054329 monotherapy at the protocol-specified starting dose in the treatment group A (TGA), with subsequent cohort escalations in the three treatment groups (TGA, TGB, and TGC) based on protocol-specific criteria</description>
    <arm_group_label>INCB054329 Monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Confirmed diagnosis of advanced malignancy:

               -  Treatment Group A (TGA): Part 1 and Part 2: Any advanced solid tumor or lymphoma;
                  Part 3: Histologically confirmed disease in specific solid tumors and lymphomas

               -  Treatment Group B (TGB): Acute Leukemia (Part 3 - acute myeloid leukemia [AML]
                  only), myelodysplastic syndrome (MDS), myelodysplastic /myeloproliferative
                  neoplasms (MDS/MPN) and myelofibrosis (MF)

               -  Treatment Group C (TGC): Multiple myeloma

          -  Progressed following at least 1 line of prior therapy and there is no further approved
             therapy available that has been demonstrated to prolong survival (including subjects
             who are intolerant to the approved therapy)

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 in Parts 1 and
             2 dose escalation and titration, and 0, 1, 2 in Part 3 dose expansion

        Key Exclusion Criteria:

          -  Inadequate hematopoietic, liver, endocrine or renal function

          -  Receipt of anticancer medications or investigational drugs within the following
             interval before the first administration of study drug:

               -  &lt; 6 weeks for mitomycin-C or nitrosoureas

               -  &lt; 5 half-lives or 14 days, whichever is longer, for any investigational agent
                  (for any indication)

               -  &lt; 28 days for any antibodies or biological therapies

               -  &lt; 5 half-lives for all other anticancer medications, or sponsor approval

          -  Prior radiotherapy within 2 weeks prior to first dose of study drug

          -  Untreated brain or central nervous system (CNS) metastases

          -  Type 1 diabetes or uncontrolled Type 2 diabetes

          -  Any sign of clinically significant bleeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fred Zheng, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco, Medical Center at Mount Zion</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute Research Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Horizon Oncology Center</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287-0013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-0021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2015</study_first_submitted>
  <study_first_submitted_qc>April 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2015</study_first_posted>
  <last_update_submitted>February 2, 2018</last_update_submitted>
  <last_update_submitted_qc>February 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>solid tumor</keyword>
  <keyword>lymphoma</keyword>
  <keyword>BET bromodomain inhibitor</keyword>
  <keyword>BRD</keyword>
  <keyword>Diffuse large B-cell lymphoma (DLBCL)</keyword>
  <keyword>Burkitt's lymphoma</keyword>
  <keyword>c-MYC</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>Pancreatic adenocarcinoma</keyword>
  <keyword>castration-resistant prostate cancer</keyword>
  <keyword>breast cancer</keyword>
  <keyword>NUT midline carcinoma</keyword>
  <keyword>leukemia</keyword>
  <keyword>acute myeloid leukemia (AML)</keyword>
  <keyword>atypical chronic myeloid leukemia (aCML)</keyword>
  <keyword>myelodysplastic syndrome (MDS)</keyword>
  <keyword>myeloproliferative neoplasms</keyword>
  <keyword>myelofibrosis (MF)</keyword>
  <keyword>multiple myeloma (MM)</keyword>
  <keyword>CMML</keyword>
  <keyword>MDS/MPN-U</keyword>
  <keyword>RARS-T</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

